ABSTRACT To investigate the changes in pharmacologically active substances and the mechanisms of efficacy enhancement of Schisandra chinensis after processing in rats, this study employed ultra‐high performance liquid chromatography‐quadrupole‐time‐of‐flight‐tandem mass spectrometry technology to preliminarily screen and identify the prototype components and metabolites in the drug‐containing plasma of rats after oral administration of Schisandra chinensis and its processed product extracts. The results showed that 14 prototype blood‐entering components were identified in Schisandra chinensis and its processed products in both positive and negative ion modes. Compared with the raw Schisandra chinensis group, the blood‐entering response values of prototype components such as Schisantherin A and Schizandrin B in the processed products were significantly increased. In addition, this study identified a total of 43 differential metabolites, including 18 unique components specific to Schisandra chinensis , 14 common components shared by both wine‐processed Schisandra chinensis and vinegar‐processed Schisandra chinensis , five unique components specific to wine‐processed Schisandra chinensis , and six unique components specific to vinegar‐processed Schisandra chinensis . These results suggest that processing systematically enhances the material basis of the pharmacological effects of Schisandra chinensis in vivo by improving the bioavailability of active components and regulating in vivo metabolites. This provides an important reference for the quality control and clinical application of Schisandra chinensis and its processed products.
Xiao‐yuan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: